- Home
- NX vs CSTL Comparison
NX vs CSTL Comparison
Compare NX & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- CSTL
- Stock Information
- Founded
- NX 1927
- CSTL 2007
- Country
- NX United States
- CSTL United States
- Employees
- NX N/A
- CSTL N/A
- Industry
- NX Metal Fabrications
- CSTL Medical Specialities
- Sector
- NX Industrials
- CSTL Health Care
- Exchange
- NX Nasdaq
- CSTL Nasdaq
- Market Cap
- NX 660.6M
- CSTL 661.7M
- IPO Year
- NX N/A
- CSTL 2019
- Fundamental
- Price
- NX $14.47
- CSTL $24.01
- Analyst Decision
- NX
- CSTL Strong Buy
- Analyst Count
- NX 0
- CSTL 6
- Target Price
- NX N/A
- CSTL $37.67
- AVG Volume (30 Days)
- NX 572.1K
- CSTL 256.3K
- Earning Date
- NX 12-11-2025
- CSTL 11-03-2025
- Dividend Yield
- NX 2.21%
- CSTL N/A
- EPS Growth
- NX N/A
- CSTL N/A
- EPS
- NX N/A
- CSTL N/A
- Revenue
- NX $1,839,956,000.00
- CSTL $346,269,000.00
- Revenue This Year
- NX $46.73
- CSTL N/A
- Revenue Next Year
- NX $0.48
- CSTL N/A
- P/E Ratio
- NX N/A
- CSTL N/A
- Revenue Growth
- NX 70.18
- CSTL 20.40
- 52 Week Low
- NX $13.11
- CSTL $14.59
- 52 Week High
- NX $32.23
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- NX 42.67
- CSTL 56.71
- Support Level
- NX $13.99
- CSTL $23.31
- Resistance Level
- NX $15.83
- CSTL $24.64
- Average True Range (ATR)
- NX 0.54
- CSTL 0.80
- MACD
- NX 0.15
- CSTL 0.07
- Stochastic Oscillator
- NX 50.00
- CSTL 69.02
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.